1h Free Analyst Time
The musculoskeletal drugs market is forecasted to grow by USD 26.37 billion during 2023-2028, accelerating at a CAGR of 5.8% during the forecast period. The report on the musculoskeletal drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing geriatric population, rising prevalence of obesity, and growing healthcare expenditure.
The musculoskeletal drugs market is segmented as below:
By Drug Class
- Nonsteroidal anti inflammatory drugs
- Disease modifying anti rheumatic drugs
- Analgesics
- Corticosteroids
- Others
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the musculoskeletal drugs market covers the following areas:
- Musculoskeletal Drugs Market sizing
- Musculoskeletal Drugs Market forecast
- Musculoskeletal Drugs Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Drug Class
9 Market Segmentation by Distribution Channel
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global musculoskeletal drugs market: AbbVie Inc., Amgen Inc., Anika Therapeutics Inc., Astellas Pharma Inc., Bioventus LLC, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Kangstem Biotech Co Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi SA, Sorrento Therapeutics Inc., UCB SA, and Zimmer Biomet Holdings Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is adoption of ai and ml for diagnosing musculoskeletal conditions."
According to the report, one of the major drivers for this market is the increasing geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Anika Therapeutics Inc.
- Astellas Pharma Inc.
- Bioventus LLC
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilde Healthcare
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Kangstem Biotech Co Ltd.
- Novartis AG
- Oryn Therapeutics
- Pfizer Inc.
- Sanofi SA
- Sorrento Therapeutics Inc.
- UCB SA
- Zimmer Biomet Holdings Inc.
